Samir M. Hanash, M.D., Ph.D.
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Professor, Department of Clinical Cancer Prevention - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Postgraduate Training
| 1976-1978 | Clinical Residency, Pediatrics, Children's Hospital of Michigan, Ann Arbor, Michigan |
| 1972-1976 | Clinical Residency, Genetics, University of Michigan, Ann Arbor, Michigan |
Licenses & Certifications
| 1984 | American Board of Pediatrics Hematology-Oncology |
| 1982 | American Board of Pediatrics |
Experience & Service
Administrative Appointments/Responsibilities
Director, Department of Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present
Distinguished Chair, Department of Evelyn & Sol Rubenstein Distinguished Chair for Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present
Co-Director, Department of Center for Global Cancer Early Detection, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present
Editorial Activities
Editor/Service on Editorial Board(s), Precision Cancer Medicine, Fudan University Cancer Institute and Breast Cancer Center, Shanghai, China, 2018 - Present
Editor/Service on Editorial Board(s), Translational Lung Cancer Research(TLCR), 2018 - Present
Editor/Service on Editorial Board(s), Journal of Clinical Oncology, 2010 - Present
Editor/Service on Editorial Board(s), Disease Markers, 2010 - Present
Editor/Service on Editorial Board(s), Proteomics, 2010 - Present
Editor/Service on Editorial Board(s), Briefings in Functional Genomics and Proteomics, 2010 - Present
Editor/Service on Editorial Board(s), Technology in Cancer Research and Treatment, 2010 - Present
Editor/Service on Editorial Board(s), Journal of Proteome Research, 2010 - Present
Editor/Service on Editorial Board(s), Expert Review of Molecular Diagnostics, 2010 - Present
Editor/Service on Editorial Board(s), Cancer Prevention Research, 2010 - Present
Editor/Service on Editorial Board(s), Cancer Biomarkers, 2010 - Present
Editor/Service on Editorial Board(s), Human Genomics and Proteomics, 2010 - Present
Editor/Service on Editorial Board(s), Thoracic Center, 2010 - Present
Editor/Service on Editorial Board(s), Journal of Proteomics and Bioinformatics, 2010 - Present
Editor/Service on Editorial Board(s), The Protein Journal, 2010 - Present
Editor/Service on Editorial Board(s), BMC Journal, 2010 - Present
Editor/Service on Editorial Board(s), Clinical Proteomics, 2010 - Present
Editor/Service on Editorial Board(s), Genome Medicine, 2010 - Present
Honors & Awards
| 2024 | Research Excellence Award, University of Texas MD Anderson Cancer Center |
| 2017 | AACR Team Science Award for Liquid Biopsy Work |
| 2017 | Distinguished Achievement in Proteomic Sciences Award, Human Proteome Organization |
| 2016 - 2024 | Scientific Advisory Board National Center for Translational Medicine, X’ian, China |
| 2015 | Science Foundation Ireland Review Committee Chair |
| 2014 - 2024 | Scientific Advisory Board,National Center for Protein Sciences, Beijing China |
| 2013 - 2024 | Evelyn & Sol Rubenstein Distinguished Chair for Cancer Prevention, University of Texas MD Anderson Cancer Center |
| 2013 | University of Texas Stars Award |
| 2010 | Colon Cancer Alliance Scientific Advisory Board |
| 2010 | Department of Defense Lung Cancer Integration Panel |
| 2009 | Mouse Models of Human Cancer Consortium Preventative Interventions Leadership Advisory Board |
| 2008 | Dana Farber Cancer Institute Renal Spore Advisory Board |
| 2008 | Vanderbilt University Lung Cancer Spore Advisory Board |
| 2007 | Nature Biotechnology Who is Who in Biotech |
| 2007 | University of Pittsburgh Lung Cancer Spore Advisory Board |
| 2006 | Canary Foundation Scientific Advisory Board |
| 2006 | Centro De Investigacion Cooperativ, Spain Scientific Advisory Board |
| 2006 | Distinguished Service Award HUPO |
| 2006 | Northwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Advisory Board |
| 2005 | US Human Proteome Organization Executive Committee |
| 2002 | Henry Sewall Endowed Professorship, University of Michigan |
| 2002 | President, Advisory Board Genome Quebec, Canada |
| 2002 | University of Michigan Innovator Award |
| 2001 | Inaugural President, Human Proteome Organization |
| 2000 | Human Proteome Organization Board |
| 1997 | INSERM Scholar Award |
| 1996 | Curie Institute Rothschild Award |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2019. Science First: Changing the Trajectory of Lung Cancer. Conference. JLABS. Houston, TX, US.
- 2017. Proteomics Platform. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2017. Biomarker based personalized cancer risk assessment on early detection. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2017. Opportunities for diagnosing and managing chest CT screen detected lesions. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2017. Proteomics. Conference. Moonshots Program Scientific Advisory Board. Houston, TX, US.
- 2016. Blood biomarkers to increase the impact of cancer screening: application to lung cancer. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2016. MD Anderson’s work to develop a blood test to detect lung cancer, the number one cancer killer, at its earliest stages. Conference. The University of Texas M.D. Anderson Cancer Center. West Palm Beach, FL, US.
- 2016. Give Cancer the Boot Fundraising Benefiting MD Anderson. Conference. The University of Texas M.D. Anderson Cancer Center. Laredo, TX, US.
- 2016. Lung Cancer Research: A New Era for Cancer Early Detection. Conference. The University of Texas M.D. Anderson Cancer Center. Midland, TX, US.
National Presentations
- 2022. Comparison Over Conventional Screening Methods. Invited. Liquid Biopsy Surveillance & Early Detection Summit. Boston, MA, US.
- 2022. Circulating Exosomes as a Liquid Biopsy Approach for Precision Cancer Therapy. Invited. 14th Annual Next Generation Summit. Washington, DC, US.
- 2021. Early-onset Colorectal Cancer. Invited. Early Onset Colorectal Cancer Group. Austin, TX, US.
- 2020. The long journey toward developing a biomarker panel for Lung Cancer Screening. Invited. Global Oncology Summit, US.
- 2019. The Wide World of Circulating Biomarkers; The Opportunities and the Challenges. Invited. 11th Annual Early Detection Research Network (EDRN). Bethesda, MD, US.
- 2019. Mining the Proteometabolome for Precision Medicine. Invited. Applied Pharmaceutical Analysis. Boston, MA, US.
- 2019. Keynote Presentation: Circulating Exosomes and Their Cargo as a Source of Tumor Antigents. Invited. Immuno-Oncology Summit. Boston, MA, US.
- 2019. Keynote Speaker at The Proteomics Technology Day. Invited. Bristol-Myers Squibb. Princeton, NJ, US.
- 2018. Lung Cancer Early Detection and Prevention. Invited. TRDRP. San Francisco, CA, US.
- 2018. Blood Based Biomarkers. Invited. Cancer Intervention and Surveillance Modeling Network (CISNET). Bethesda, MD, US.
- 2018. Pancreatic Cancer. Invited. PanCAN Scientific Meeting. San Diego, CA, US.
- 2018. Progress Toward a Liquid Biopsy for Immune Monitoring. Invited. Next Generation Summitt 10th Annual. Washington, DC, US.
- 2018. Metabolite and protein panels as biomarkers for asymptomatic pancreatic cancer. Invited. Stand up to Cancer Pancreatic Cancer (SU2C) Mini-Summit. Philadelphia, PA, US.
- 2017. Modeling the Cyber War between the Immune System and Tumor Cells. Invited. Next Generation Summit DX 2017. Washington, DC, US.
- 2017. Biomarker based personalized cancer risk assessment on early detection. Invited. AA of Pharma Sciences and Fortune Health. San Diego, CA, US.
- 2017. Investigating and Evaluating Non-DNA Approaches for Liquid Biopsies. Invited. Precision LBx Liquid Biopsy Diagnostics. San Diego, CA, US.
- 2016. Antigen presentation by tumor cells is largely dependent on the immunoproteasome. Assessment of the status of the immunoproteasome may predict response or resistance to immunotherapeutic modalities. Invited. Eight Next Generation Diagnostics Summit. Washington, DC, US.
International Presentations
- 2022. The wide world of liquid biopsy platforms for cancer early detection. Invited. Genomics Live Congress. Basel, CH.
- 2022. Potential of biomarkers for early detection of ovarian cancer. Invited. OVACURE Foundation Ovarian Cancer Innovation Challenge. Copenhagen, DK.
- 2022. Liquid Biopsy and Cancer Early Detection. Invited. Biomarkers & Precision Oncology World Congress. Boston, US.
- 2020. The Wide World of Liquid Biopsy-Based Biomarker for Cancer Immunotherapy. Invited. 27th International Molecular Med TRI-CON Advancing Precision Medicine. San Francisco, US.
- 2020. Liquid Biopsy-Based Biomarkers for Cancer Immunotherapy: Opportunities and Challenges. Invited. 27th International Molecular Med TRI-CON Advancing Precision Medicine. San Francisco, US.
- 2019. Keynote Presentation: Liquid biopsy approaches from genomics and beyond. Invited. Precision Medicine and Channel Retreat 2019. Vancouver, CA.
- 2019. Metabolic Signatures Predictive of Tumor Immune Phenotypes. Invited. 15th Annual Biomarker World Congress. Boston, US.
- 2018. 3rd Best of AACC China, Molecular Diagnosis, Clinical Application of LS-MS, and Laboratory Medicine Big Data and Artificial Intelligence. Invited. China Medicine Education Association. Shanghai, CN.
- 2018. Lung Early Detection and Treatment of Cancer. Invited. ILCCO-TRICL Annual Meeting and 2018 World Conference on Lung Cancer. Toronto, CA.
- 2018. Biomarkers based lung cancer risk assessment and early detection. Invited. The University of Nice Côte d’Azur. Nice, FR.
- 2018. Profiling the Tumor Immune Microenvironment by Means of Liquid Biopsy. Invited. Cambridge Healthtech Institutes 14th Annual World Congress. Boston, US.
- 2018. Lung Early Detection and Treatment of Cancer Clinical Study. Conference. Cancer Institute Chinese Academy of Medical Sciences. Beijing, CN.
- 2018. Drug discovery beyond genomics. Invited. Fudan University. Shanghai, CN.
- 2017. Cancer metabolism and epigenetic gene regulation. Invited. Qingdao University Faculty of Medicine Symposium. Quingdao, CN.
- 2017. Implementation of Liquid Biopsy into the Point of Care. Invited. HUPO2017 Congress Workshop. Dublin, IE.
- 2017. Biomarker based personalized cancer risk assessment on early detection. Invited. Zhenjian University. Zhejian, CN.
- 2017. Immune Profiling in Cancer Track. Invited. Biomarkers, Diagnostics and Immunotheraphy World Congress 2017. Philadelphia, US.
- 2017. Blood Based Signatures for Lung Cancer Screening. Invited. Lung Cancer Screening Conference. Paris, FR.
- 2017. Lung Early Detection Cancer Clinical Study in China. Conference. Moonshots Project. Beijing, CN.
- 2017. Lung Early Detection Cancer The MD Anderson Moonshots Experience. Invited. Debiopharm. Geneva, CH.
- 2016. Dynamic suppression of antigen presentation by tumor cells through modulation of the immunoproteasome. Invited. Shanghai Jiao Tong University. Shanghai, CN.
- 2016. Multi-international Study for Early Detection of Lung Cancer. Invited. ICAPS Conference International. 'Viena, AT.
- 2016. Dynamic suppression of antigen presentation by tumor cells through modulation of the immunoproteasome. Invited. Istituto Veneto di Scienze, Lettere ed Arti, Palazzo Cavalli Franchetti, Campo S. Stefano. Venice, IT.
- 2016. Lung Cancer Early Detection and Treatment of Cancer. Invited. 1st West China International Conference on Lung Cancer. Sichuan, CN.
- 2016. Strategies for the Development of Cancer Biomarkers Using Proteomics: What Works and What Does not Work. Invited. EuPA X Annual Congress of the European Proteomics Association. Istanbul, TR.
- 2016. Global Cancer: Occurrence, Causes, and Avenues to Prevention. Invited. LC3/ILCCO Annual Consortium Meeting, IARC 50th Anniversary Conference. Lyons, FR.
- 2016. Strategies for the Development of Blood Based Lung Cancer Biomarkers for Screening: What Works and What Does Not Work. Invited. Pioneer Century Science. Budapest, HU.
Formal Peers
- 2018. Alliance Pancreatic Cancer Consortia Workshop. Invited. Washington, DC, US.
- 2018. Lung Cancer Early Detection and Biomarker Validation Study in China and MD Anderson Cancer Center. Visiting. Beijing, CN.
- 2018. Women's Health Initiative Breast Cancer. Invited. Seattle, WA, US.
- 2018. The Continuum of Risk Assessment and Early Detection through Blood Based Biomarkers. Invited. Washington, DC, US.
- 2018. Small Cell Lung Cancer Consortium. Invited. Washington, DC, US.
- 2018. Lung Cancer Biomarkers. Invited. Paris, FR.
- 2018. Women's Health Initiative pre-diagnosis of lung and breast cancer. Invited. Seattle, WA, US.
- 2018. Development of blood based biomarkers for cancer screening. Invited. Houston, TX, US.
- 2016. Blood Biomarkers to Increase the Impact of Cancer Screening: Application to Lung Cancer. Invited. Duarte, CA, US.
- 2016. Integrating Biomarkers into Lung Cancer Screening. Invited. Pittsburgh, PA, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Validation of blood-based biomarkers for risk assessment of lung cancer among individuals with no smoking history in the PLCO Cohort |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | U01CA295902 |
| Date: | 2025 - 2029 |
| Title: | Team DEFIANT: DEFIning ActioNable Targets for Osteosarcoma |
| Funding Source: | Break Through Cancer |
| Role: | Co-I |
| ID: | FP00026454 |
| Date: | 2025 - 2030 |
| Title: | MD Anderson Sarcoma SPORE |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | P50CA302482 |
| Date: | 2025 - 2025 |
| Title: | SIV/OTC Quest PROMISE program |
| Funding Source: | Quest Diagnostics Inc |
| Role: | PI |
| ID: | AWD00009389 |
| Date: | 2025 - 2030 |
| Title: | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA299972 |
| Date: | 2025 - 2029 |
| Title: | Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP250269 |
| Date: | 2025 - 2029 |
| Title: | AI-Enabled, Digital Companion Learning for Protein-Targetable Cancer Phenotypes |
| Funding Source: | The University of Texas Austin & MD Anderson Cancer Center |
| Role: | Co-I |
| ID: | N/A |
| Date: | 2024 - 2026 |
| Title: | Gastroesophageal Cancer Patients’ Family Matters |
| Funding Source: | Torrey Coast Foundation |
| Role: | Co-I |
| ID: | FP00023473 |
| Date: | 2024 - 2028 |
| Title: | Pediatric Bone Sarcoma (PBS) centric target and immune therapy discovery |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240440 |
| Date: | 2023 - 2026 |
| Title: | Roche Lung Assessment |
| Funding Source: | Roche Diagnostics |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | EXoPERT Diagnostics |
| Funding Source: | EXoPERT Corporation |
| Role: | PI |
| Date: | 2023 - 2027 |
| Title: | Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | U01CA282216 |
| Date: | 2023 - 2028 |
| Title: | Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA281727 |
| Date: | 2023 - 2026 |
| Title: | Manaolana Novel Therapeutics |
| Funding Source: | Manaolana Oncology |
| Role: | Co-PI |
| Date: | 2023 - 2028 |
| Title: | Repurposing glucosylceramide synthase to promote mitochondrial lethality and potentiate an anti-tumor immune response in triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R37CA269611 |
| Date: | 2023 - 2027 |
| Title: | Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA276235 |
| Date: | 2022 - 2027 |
| Title: | Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA277133 |
| Date: | 2022 - 2026 |
| Title: | RadioPharm Ventures Novel Targets |
| Funding Source: | RadioPharm Ventures |
| Role: | Co-PI |
| Date: | 2022 - 2027 |
| Title: | Clinical Validation Center for Lung Cancer Early Detection |
| Funding Source: | NIH |
| Role: | PI |
| ID: | U01CA271888 |
| Date: | 2022 - 2027 |
| Title: | Clinical Validation Center for Early Detection of Pancreatic Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | U01CA200468 |
| Date: | 2022 - 2027 |
| Title: | Fred Hutchinson Breast Cancer Clinical Validation Center |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 2U01CA152637 |
| Date: | 2022 - 2027 |
| Title: | Common Stem Cell Origin of Junctional and Gastric Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA27906 |
| Date: | 2022 - 2027 |
| Title: | Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life Expectancy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA271187 |
| Date: | 2021 - 2026 |
| Title: | Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Sub-PI |
| ID: | U01 CA239522 |
| Date: | 2019 - 2026 |
| Title: | Cancer Center Support (CORE) Grant |
| Funding Source: | NCI |
| Role: | Co-Leader |
| ID: | P30CA016672-47 |
Selected Publications
Peer-Reviewed Articles
- Creighton CJ, Nagaraja AK, Hanash SM, Matzuk MM, Gunaratne PH. A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA 14(11):2290-6, 2008. e-Pub 2008. PMID: 18812437.
Book Chapters
- Wang H, Hanash SM. Intact Protein Analysis System for discovery of serum-based disease biomarkers. In: Serum Plasma Proteomics. Humana Press, 2011.
- Wang H, and Hanash SM. Electrospray mass spectrometry for quantitative plasma profiling. In: Proteomics, Methods and Protocols. Humana Press, 2009.
- Hanash SM. Proteomics technologies. In: Systems Biomedicine. Elseviers, 2009.
- Faca V, Wang H, and Hanash SM. Proteomic global profiling for cancer biomarker discovery. In: Mass specrometry of proteins and peptides. Humana Press, 2009.
- Hanash SM. Translational implications of proteomics. In: Handbook of Cell Signaling. Elsevier, 2009.
- Hanash SM. Current proteomics. In: Essentials of Genomics and Bioinformatics. Wiley, 2006.
- Creighton C, and Hanash SM. Informatics tools for functional pathway analysis using genomics and proteomics. In: Informatics in proteomics. Taylor and Francis, 2005.
- Hanash SM. Diagnostic applications of protein microarrays. In: Medical Biomethods Handbook, 2005.
- Hanash SM. Application of proteomics to disease diagnostics. In: Molecular Diagnostics, 2005.
- Hanash SM. Clinical applications of proteomics. In: Proteome Analysis: Interpreting the Genome. Elsevier Science B.V, 225-237, 2004.
- Hanash SM. The role of proteomic analyses in breast cancer. In: Diseases of the 3rd Edition. Lippincott, Williams & Wilkins, 427-431, 2004.
- Hanash SM, Richard B, Beer D. Relevance of DNA methylation to lung cancer. In: Lung Tumors: Fundamental Biology and Clinical Management. Marcel Dekker, 1999.
- Hanash SM. Gel Electrophoresis of Proteins: A Practical Approach. In: Two-Dimensional Gel Electrophoresis. Oxford University Press, 189-211, 1998.
- Neel JV, Asakawa J, Kuick R, Hanash SM, and Satoh C. Studies on the genetic effects of the atomic bombs: Past, present and future. In: Effects of Ionizing Radiation: Atomic Bomb Survivors and Their Children (1945-1995). Joseph Henry Press, 159-175, 1998.
- Satoh C, Kodaira M, Asakawa J, Takahashi N, Kuick R, Hanash SM, and Neel JV. Techniques for detecting the genetic effects of the atomic bombings applicable to the study of the genetic effects of natural radiation. In: High Levels of Radiation 1996 Radiation Dose and Health Effects. Elsevier Science B.V, 385-390, 1997.
- Hanash SM, Richardson B, Kuick R, Wimmer K, Thoraval DH, Lamb B, Nambu Y, and Beer D. DNA methylation changes in lung cancer. In: Clinical and Biological Basis of Lung Cancer Prevention. Birkhauser Verlag Basel, 157-167, 1997.
- Hanash SM, Ungar D, and Strahler JR. Differentation and proliferation related expression of the heat shock protein hsp27, a novel marker in cancer. In: Biologie Prospective, Comptes rendus du 8e Colloque de Pont-a-Mousson. John Libbey Eurotext, 645-650, 1993.
- Hanash SM, Richard B, and Beer D. Revelance of DNA methylation to lung cancer in Lung. In: Fundamental Biology and Clinical Management, 1992.
- Strahler JR, Kuick R, Piviorotto S, Somerlot L, Chu EH, and Hanash SM. High Resolution Two-Dimensional Polycrylamide Gel Electrophoresis of Mutant Polypeptides Using Narrow Range Immobilized pH Gradients in the First Dimension. In: Progress in Two-Dimensional Electrophoresis. Verlag Chemie, 256-262, 1989.
- Neel JV, Strahler JR, Hanash SM, Kuick R, Chu EH. 2-D PAGE and Genetic Monitoring:Progress, Prospects, and Problems. In: Progress in Two-Dimensional Electrophoresis. Verlag Chemie, 79-89, 1989.
- Eckerskorn C, Strahler J, Hanash SM, and Lottpeich F. Identification and Characterization of Proteins After 2-D Electrophoresis by Microsequence Analysis Demonstrated with Leukemia Protein Markers. In: Progress in Two_Dimensional Electrophoresis. Verlag Chemie, 157, 1989.
- Teichroew D, Hanash SM, Kuick R, Ting J, Beaver A. A Strategy for the Design of a Laboratory Information Processing System for 2D Gel Studies. In: Progress in Two-Dimensional Electrophoresis. Verlag Chemie, 37-52, 1989.
- Strahler JR, Kuick R, Hanash SM. Protein Structure: A Practical Approach. In: Two-Dimensional Electrophoresis. IRL Press, 65-92, 1989.
- Hanash SM. Contribution of Protein Electrophoretic Analysis to Cancer Research. In: Advances in Electrophoresis, 1-44, 1988.
- Chu EH, Boehnke M, Hanash SM, Kuick R, Neel JV, Strahler JR. Human somatic mutation rates in vitro. In: Proc. XVI Intern. Genome, 1988.
- Hanash SM. A New Generation of Polypeptide Markers in Leukemia. In: Electrophoresis Forum. Proceedings, 106-113, 1987.
- Hanash SM. Clinical Applications for Two-Dimensional Electrophoresis. Problems and Promises. In: Progress in Two-Dimensional Electrophoresis. Masson Inc, 197-204, 1986.
- Boerwinkle E, Sing CF, Hanash SM, Siest, G. The Analysis of Genetic Variability Using Two-Dimensional Electrophoresis. In: The Analysis of Genetic Variability Using Two-Dimensional Electrophoresis. Masson, Inc, 149-157, 1986.
- Kuick, R, Hanash SM, Sing, CF. An Interactive Multigel Matching Strategy with an Application to Multiple Tissues. In: Progress in Two-Dimensional Electrophoresis. Masson, Inc, 91-96, 1986.
- Hanash SM. Second Dimension in Two-Dimensional Electrophoresis. In: Progress in Two-Dimensional Electrophoresis. Masson, Inc, 38-46, 1986.
- Strahler, JR, Rosenblum, BB, Hanash SM. Hemoglobin Beirut (val-ala) Synthesis in Erythroid Cultures. In: Protides of Biological Fluids. Pergamon, 1157-1160, 1985.
- Hanash SM, Gagnon, M, Seeger, RC. Analysis of Neuroblastoma Cell Proteins Using Two-Dimensional Electrophoresis. In: Advances in Neuroblastoma. Alan R. Liss, Inc, 261-268, 1985.
- Rosenblum, BB, Strahler, JR, Hanash SM, Whitten, CF, Butkunas, R, Roberts, A. Peripheral Blood Erythroid Progenitors from patients with Sickle Cell Anemia: HPLC Separation of Hemoglobins and the Effect of a HbF Switching Factor. In: Experimental Approches for the Study of Hemoglobins Switching. Alan R. Liss, Inc, 397-410, 1985.
- Hanash SM, Baier, LJ, Schwartz, S. Polypeptides Differences Between T-lymphocytes and T-lymphoblasts Detected by by Two-Dimensional Electrophoresis. In: Electrophoresis '83. DeGruyter and Co, 203-210, 1984.
- Baier, LJ, Hanash SM, Erickson, RP. Mouse Liver Protein Variants Detected by Two-Dimensional Electrophoresis. In: Electrophoresis '83. DeGruyter and CO, 350-357, 1984.
- Rosenblum, BB, Hanash SM. Two-Dimensional Gel Analysis of Proteins in Mature Erythroid Bursts,IN. In: Electrophoresis '83. DeGruyter and Co, 180-186, 1984.
- Neel, JV, Rosenblum, BB, Sing, CF, Skolnick, MM, Hanash SM, Sternberg A, S. Adapting Two-Dimensional Gel Electrophoresis to the Study of Human Germ-Line Mutation Rates. In: Two-Dimensional Gel Electrophoresis of Protein, Methods and Applications. Academic Press, 259-306, 1984.
- Aster, JC, Rosenblum, BB, Brewer, G, Hanash SM. Analysis of Protein 4.1 Structural Variation Two-Dimensional Polyacrylamide Gel Electrophoresis. In: The Red Cell Membrane. Alan R. Liss, Inc, 60-68, 1984.
- Aster, JC, Rosenblum, BB, Brewer, GJ, and Hanash SM. Erythrocyte Membranes: Recent Clinical and Experimental Advances. In: Analysis of Protein 4.1 Structural Variation Using Two-Dimensional Polyacrylamide Gel Electrophoresis. Alan R. Liss inc, 73-88, 1984.
- Rahim-Pour, A, Steinmetz, J, Hanash SM. Proceedings, IVth Int. In: Separation of Plasma Lipoprotein Fractions by Two-Dimensional Electrophoresis. Prospective Biology Colloquium, 91-94, 1983.
- Rosenblum, BB, Hanash SM, Neel A, JV. Application to Genetic Analysis. In: High Resolution Separation of Plasma Protiens. Fifth Int. Prospective Biology Colloquium, 85-90, 1983.
- Neel, JV, Mohrenweiser, H, Hanash SM, Rosenblum, BB, Sternberg, S, Wurzinger, K, Rothman, E, Satoh, C, Goriki, K, Krasteff, T, Long, M, Skolnick, M, Krzesicki, k R. Utilization of Mammalian Specific Locus Studies in Hazard Evaluation and Estimation of Genetic Risk. In: Approches to Monitoring Human Population of Germinal Mutation Rates:. Plenum Press, 71-93, 1983.
- Rucknagel, DL, Ladu, CS, Reynolds, FJ, Hanash SM, Whitten A, CF. Advances in Hemoglobin Analysis. In: Immunologic Quantitation of Fetal Hemoglobin in Sickle Cell Anemia. Alan R. Liss Inc, 94-99, 1981.
- Hanash SM, Kavadella, M, Amanullah, A, Scheller, K, Bunnell, K. Advances in Hemoglobin Analysis. In: High Performance Liquid Chromatography of Hemoglobins: Factors Affecting Resolution. Alan R. Liss, Inc, 53-67, 1981.
- Hanash SM, Rucknagel A, DL. Advances in Hematology. In: Clinical Implications of Recent Advances in Hemoglobin Disorders. Med. Clini North Ameri.,64, 776-800, 1980.
- Winter, WP, Rucknagel, DL, and Hanash SM. Advances in Human Genetics. In: Genetic Mechanisms Contributing to the Expression of Human Hemoglobin Loci. Harris, H. and HirschornK, 229-291, 1979.
- Rucknagel DL, Hanash SM, Sing CF, Winter WP, Whitten CF, and Prasad AS. In: Age and Sex Effects of Hemoglobin F in Sickle Cell Anemia in Celluar and Molecular Regulation of Hemoglobin Switching. Grune and Stratton, 107-118, 1978.
- Rucknagel DL, Baine RM, Hanash SM, and Winter WP. Proc. XVI Int. Conference on Hematology. In: Polymorphism in the Number of Hemoglobin Alpha Chain. Red Cell Structure and Metabolism, Alan R Liss, Inc, 63-73, 1978.
- Winter WP, Rucknagel DL, and Hanash SM. Proc. XVI Int. Congress of Hematology. In: Heat denaturation and degradation of hemoglobin. Excerpta Medica, Amsterdam, 307-309, 1976.
- Rucknagel DL, Baine R, Hanash SM, and Winter W. Proc. XVI Int. Congress of Hematology. In: Dosage of Hemoglobin Alpha Chain Genes and Regulation of Hemoglobin Syntheis. Excerpta Medica, Amsterdam, 174-176, 1976.
- Hanash SM, Taguchi A. Cancer Proteomics. In: Molecular Oncology: Causes of Cancer and Targets for Treatment, 52-57.
Patents
- Hanash S. Methods for the detection and treatment of lung cancer. Patent Number: 62456729 MDA REF 0025101.
- Hanash S. Methods for the detection and treatment of pancreatic cancer. Patent Number: MDA17-008.
- Hanash, Samir M, Misek, David, Hinderer, Robert, Prasannan, Latha. Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum. Patent Number: 6,677,128.
- Hanash, Samir M, Rickman, David, Tyagi, Rachana, Zhu, Xiao-Xiang, Kish, Phillip. Treatments and markers for cancers of the central nervous system. Patent Number: 6,680,172.
- Hanash, Samir M, Brichory, Franck. Detection and treatment of cancers of the lung. Patent Number: 7,202,045.
- Nam, Myeong, Madoz-Gurpide, Juan, Wang, Hong, Misek, David E, Hanash, Samir M. Detection and treatment of cancers of the colon. Patent Number: 7,319,010.
- Hanash, Samir M, Beretta, Laura, LeNaour, Francois. Detection and treatment of cancers of the liver. Patent Number: 7,387,881.
- Hanash, Samir M, Misek, David, Hinderer, Robert, Beer, David, Brichory, Franck. Annexin proteins and autoantibodies as serum markers for cancer. Patent Number: 7,759,081.
Patient Reviews
CV information above last modified March 09, 2026